SuperworthAmgen Inc. AMGN
Drug Manufacturers - General, Healthcare
$413.08
+2.60%
- Market cap
- $223.3B
- PE
- 25.7×
- 10y median 21.0×
- Forward PE
- Price to sales
- 5.9×
- EV/EBIT
- 23.3×
- Revenue, 12 months
- $38.1B
- +9% on a year ago
- Net margin
- 23.0%
- Free cash flow yield
- 4.6%
Amgen trades at 25.7× trailing earnings, pricier than 75% of the last ten years. Revenue was $38.1B over the last twelve months, up 9% on a year earlier with a 23% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.2B | $7.4B | $8.4B | $8.5B | $9.1B+11% | $8.1B+9% | $9.2B+9% | $9.6B+12% | $9.9B+9% | $8.6B+6% | $10.1B+10% | |
| Cost of revenue | $3.1B | $3.2B | $3.2B | $3.3B | $3.1B+0% | $3B−7% | $3B−7% | $3.1B−7% | $3B−4% | $2.7B−8% | $2.8B−7% |
| Gross profit | $5.1B | $4.2B | $5.2B | $5.2B | $6B+18% | $5.2B+22% | $6.2B+20% | $6.5B+25% | $6.9B+15% | $5.9B+13% | $7.2B+17% |
| R&D | $1.5B | $1.3B | $1.4B | $1.4B | $1.7B+12% | $1.5B+11% | $1.7B+21% | $1.9B+31% | $2.1B+24% | $1.7B+16% | $1.9B+7% |
| SG&A | $2.3B | $1.8B | $1.8B | $1.6B | $1.9B−17% | $1.7B−7% | $1.7B−5% | $1.7B+6% | $2B+4% | $1.6B−5% | $1.7B+3% |
| $1.3B | $991M | $1.9B | $2B | $2.3B+82% | $1.2B+19% | $2.7B+39% | $2.5B+23% | $2.7B+18% | $2.7B+126% | $3.5B+32% | |
| Interest expense | $821M | $824M | $808M | $776M | $747M−9% | $723M−12% | $708M−12% | $685M−12% | $653M−13% | $657M−9% | $673M−5% |
| Pre-tax income | $852M | −$68M | $794M | $3.1B | $782M−8% | $2B | $1.6B+98% | $3.9B+26% | $1.5B+94% | $2.1B+6% | $2.8B+77% |
| $85M | $45M | $48M | $271M | $155M+82% | $243M+440% | $136M+183% | $705M+160% | $181M+17% | $265M+9% | $393M+189% | |
| Net income | $767M | −$113M | $746M | $2.8B | $627M−18% | $1.7B | $1.4B+92% | $3.2B+14% | $1.3B+113% | $1.8B+5% | $2.4B+66% |
| $1.42 | −$0.21 | $1.38 | $5.22 | $1.16−18% | $3.20 | $2.65+92% | $5.93+14% | $2.45+111% | $3.34+4% | $4.37+65% | |
| 540M | 536M | 541M | 542M | 542M+0% | 541M+1% | 541M+0% | 542M+0% | 543M+0% | 544M+1% | 544M+1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Amgen's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| MRKMerck & Co., Inc. | $352.3B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| ABBVAbbVie Inc. | $479.5B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| JNJJohnson & Johnson | $622.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| Peer median | $352.3B | 39.3× | 24.2× | 5.3× | +5% | 9.8% |
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .